William Blair Investment Management LLC Has $48.70 Million Holdings in Evolent Health, Inc $EVH

Key Points

• William Blair Investment Management LLC reduced its stake in Evolent Health by 1.8%, holding approximately $48.70 million worth of shares as of its latest SEC filing.
• Shares of Evolent Health have declined 3.7%, with a current market price of $7.51, reflecting a wide range between a 1-year low of $7.06 and a high of $25.25.
• Analysts have mixed views on Evolent Health, with a consensus rating of "Moderate Buy" and an average price target of $15.85, indicating potential for future growth.

William Blair Investment Management LLC decreased its position in shares of Evolent Health, Inc (NYSE:EVH - Free Report) by 1.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,324,883 shares of the technology company's stock after selling 79,054 shares during the quarter. William Blair Investment Management LLC owned about 3.68% of Evolent Health worth $48,698,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Parallel Advisors LLC increased its holdings in shares of Evolent Health by 82.6% during the second quarter. Parallel Advisors LLC now owns 3,487 shares of the technology company's stock valued at $39,000 after acquiring an additional 1,577 shares in the last quarter. Banque Cantonale Vaudoise bought a new stake in shares of Evolent Health during the first quarter valued at approximately $25,000. Rhumbline Advisers increased its holdings in shares of Evolent Health by 2.1% during the first quarter. Rhumbline Advisers now owns 169,918 shares of the technology company's stock valued at $1,609,000 after acquiring an additional 3,527 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Evolent Health by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company's stock valued at $1,217,000 after acquiring an additional 3,572 shares in the last quarter. Finally, US Bancorp DE increased its holdings in shares of Evolent Health by 291.0% during the first quarter. US Bancorp DE now owns 5,153 shares of the technology company's stock valued at $49,000 after acquiring an additional 3,835 shares in the last quarter.

Evolent Health Stock Down 3.7%

Shares of NYSE:EVH opened at $7.51 on Friday. The company has a market capitalization of $882.50 million, a PE ratio of -4.66 and a beta of 0.66. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.01 and a quick ratio of 1.01. The business has a fifty day moving average price of $8.83 and a two-hundred day moving average price of $9.31. Evolent Health, Inc has a 1 year low of $7.06 and a 1 year high of $25.25.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings data on Tuesday, June 4th. The technology company reported $0.21 earnings per share (EPS) for the quarter. Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The firm had revenue of $427.70 million during the quarter. Analysts forecast that Evolent Health, Inc will post 0.08 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on EVH. Canaccord Genuity Group restated a "buy" rating and set a $16.00 price objective on shares of Evolent Health in a report on Tuesday, September 9th. Truist Financial upped their price target on Evolent Health from $14.00 to $16.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Evolent Health in a report on Wednesday, October 8th. Stephens reiterated an "equal weight" rating and set a $9.00 price target on shares of Evolent Health in a report on Wednesday, September 24th. Finally, BTIG Research reiterated a "buy" rating and set a $20.00 price target on shares of Evolent Health in a report on Tuesday, September 30th. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $15.85.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.